Interní Med. 2017; 19(3): 142-144 | DOI: 10.36290/int.2017.050
News and trends in antibiotic therapy
- Ústav lékařské mikrobiologie FN Motol, Praha
Current antibiotic treatment is marked by a rapidly increasing resistance of microorganisms to antibiotics. Some educated estimates
suggest that over several years can occur a real crisis of antimicrobial therapy, or even the beginning of the postantibiotic era. Developing
new products is not enough to adequately respond to the changing epidemiological situation, therefore, it is an attempt
to realize the full potential and older products.It is essential to reduce excessive consumption of antibiotics and in indicated cases
administered them in such a way as to minimize the risk of a further spread of resistance. The basic condition for preserving the
effectiveness of antibiotics is a knowledge and respect for the principles of rational antibiotic therapy.
Keywords: antimicrobial resistence, rational antibiotic therapy, new antibiotics
Received: August 25, 2019; Revised: November 3, 2019; Accepted: November 3, 2019; Prepublished online: November 3, 2019; Published: July 1, 2017 Show citation
References
- Bassetti M, Righi E. New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. Curr Opin Crit Care 2015; 21: 402-411.
Go to original source... 
Go to PubMed... - Titelman E, Karlsson IM, Ge Y, et al. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2011; 70: 137-141. Go to original source... Go to PubMed...
- Pillar CM, Stoneburner A, Shinabarger DL, Krause KM, Nichols WW. The postantibiotic effect and post-?-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria. Lett Appl Microbiol. 2016; 63: 96-102. Go to original source... Go to PubMed...
- Walkty A, Adam H, Baxter M, et al. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. Antimicrob Agents Chemother 2014; 58: 2554-2563. Go to original source... Go to PubMed...
- Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010; 70: 859-886. Go to original source... Go to PubMed...
- Oldach D, Clark K, Schranz J, et al. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother 2013; 57: 2526-2534. Go to original source... Go to PubMed...
- Giske CG. Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin. Clin Microbiol Infect. 2015; 21(10): 899-905. Go to original source... Go to PubMed...
- European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe, 2013. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2014.
- Hasman H, Hammerum AM, Hansen F, et al. Detection of mcr-1 encoding plasmid-mediated colistin-resistant Escherichia coli isolates from human bloodstream infection and imported chicken meat. Denmark. Euro Surveill 2015; 10: 20. Go to original source... Go to PubMed...
- Fajfr N, Louda M, Paterová P, et al. Fosfomycin trometamol - staronové antibiotikum v urologické praxi. Urol. praxi 2015; 16(4): 148-150.
- Nicolle LE. Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother 2000; 46(Suppl. 1): 35-39. Go to original source...
- Huang TD, Poirel L, Bogaerts P,et al. Temocillin and piperacillin/tazobactam resistance bydisc diffusion as antimicrobial surrogate markers for the detection of carbapenemase-producing Enterobacteriaceae in geographical areas with a high prevalence of OXA-48 producers. J Antimicrob Chemother 2014; 69: 445-450. Go to original source... Go to PubMed...
- Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014; 6: 25-64. Go to original source... Go to PubMed...
- Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011; 377(9759): 63-73. Go to original source... Go to PubMed...